Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant: ECI grants in Maternal, Reproductive, Child & Youth Health

University of Alberta

$71,853.00

Neuroprotective agents for cerebral malaria

FY 2017-18

Summary
Malaria is the third leading cause of death in children globally. In Canada, we see about 400 cases per year, especially among new immigrants and travellers returning from the tropics. It mostly affects young children in sub-Saharan Africa, who are at risk of severe disease, death, and mental disability following infection. Cerebral malaria is a deadly complication which occurs when the brain is involved. Despite the world's best antimalarial drugs, the mortality rate is still about 20%, meaning that one in five children with cerebral malaria will die of their infection. Furthermore, 25% (one in four) children who survive cerebral malaria will be left with lasting brain problems. New treatment strategies are needed to reduce the number of deaths as well as the long term effects of cerebral malaria on the brain. We think that some newly licensed drugs for cancer and brain disorders can be used for an entirely different purpose: to protect the brain in cerebral malaria. This surprising re-purposing of new medications makes sense because these drugs target molecules which govern the leakiness of vessels and brain swelling. By targeting these molecules, we think that we can improve outcomes in cerebral malaria. We want to test these drugs in 2 ways: a model of the blood brain barrier using cells in a "petri dish," and an animal model of disease. We will test these drugs to see if they can protect the brain by stabilizing the "blood-brain barrier" which separates the brain cells from the bloodstream. If we find promising molecules, this will be significant because it will suggest new treatments that could be tried in clinical trials of children with cerebral malaria.
Program
Operating Grant: ECI grants in Maternal, Reproductive, Child & Youth Health
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
366228
Name
Hawkes Michael T
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Operating Grant: New Investigator Grants in Maternal, Reproductive, Child & Youth Health
Projecttitle
Neuroprotective agents for cerebral malaria
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$71,853
Cihrequipment2
$0
Programname2
Operating Grant: ECI grants in Maternal, Reproductive, Child & Youth Health
Keyworddelim
Blood-Brain Barrier; Cerebral Malaria; Sphingosine-1 Phosphate; Tyrosine Kinase Inhibitors
Abstract
Malaria is the third leading cause of death in children globally. In Canada, we see about 400 cases per year, especially among new immigrants and travellers returning from the tropics. It mostly affects young children in sub-Saharan Africa, who are at risk of severe disease, death, and mental disability following infection. Cerebral malaria is a deadly complication which occurs when the brain is involved. Despite the world's best antimalarial drugs, the mortality rate is still about 20%, meaning that one in five children with cerebral malaria will die of their infection. Furthermore, 25% (one in four) children who survive cerebral malaria will be left with lasting brain problems. New treatment strategies are needed to reduce the number of deaths as well as the long term effects of cerebral malaria on the brain. We think that some newly licensed drugs for cancer and brain disorders can be used for an entirely different purpose: to protect the brain in cerebral malaria. This surprising re-purposing of new medications makes sense because these drugs target molecules which govern the leakiness of vessels and brain swelling. By targeting these molecules, we think that we can improve outcomes in cerebral malaria. We want to test these drugs in 2 ways: a model of the blood brain barrier using cells in a "petri dish," and an animal model of disease. We will test these drugs to see if they can protect the brain by stabilizing the "blood-brain barrier" which separates the brain cells from the bloodstream. If we find promising molecules, this will be significant because it will suggest new treatments that could be tried in clinical trials of children with cerebral malaria.
Competitiondate
201705
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hawkes, Michael T
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Human Dev &Child &Yth~ $71,853~ $0~
University of Alberta - $71,853 Grant (2017-18) | Canada Spends